NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more
NEWRON PHARMACEUT. EO-20 (NP5) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 21.242x
Based on the latest financial reports, NEWRON PHARMACEUT. EO-20 (NP5) has a cash flow conversion efficiency ratio of 21.242x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€33.60 Million) by net assets (€1.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NEWRON PHARMACEUT. EO-20 - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how NEWRON PHARMACEUT. EO-20's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NEWRON PHARMACEUT. EO-20 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NEWRON PHARMACEUT. EO-20 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FIREWEED METALS CORP.
F:M0G
|
N/A |
|
Storytel AB (publ)
PINK:STRYF
|
0.121x |
|
Synopex Inc
KQ:025320
|
0.071x |
|
Jiangsu Bide Science and Technology Co. Ltd.
SHG:605298
|
0.025x |
|
EPIC Suisse AG
SW:EPIC
|
0.034x |
|
Danhua Chemical Technology Co Ltd A
SHG:600844
|
0.043x |
|
Hollyland China Electronics Technology Corp Ltd
SHE:002729
|
0.037x |
|
Chongqing Water Group Co Ltd
SHG:601158
|
0.035x |
Annual Cash Flow Conversion Efficiency for NEWRON PHARMACEUT. EO-20 (2005–2024)
The table below shows the annual cash flow conversion efficiency of NEWRON PHARMACEUT. EO-20 from 2005 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €1.46 Million | €-17.61 Million | -12.081x | -3663.28% |
| 2023-12-31 | €-29.91 Million | €-10.14 Million | 0.339x | -57.12% |
| 2022-12-31 | €-14.03 Million | €-11.09 Million | 0.791x | +121.46% |
| 2021-12-31 | €3.11 Million | €-11.45 Million | -3.684x | -307.54% |
| 2020-12-31 | €17.25 Million | €-15.59 Million | -0.904x | -51.35% |
| 2019-12-31 | €36.80 Million | €-21.98 Million | -0.597x | -105.27% |
| 2018-12-31 | €54.84 Million | €-15.95 Million | -0.291x | -134.45% |
| 2017-12-31 | €67.72 Million | €-8.40 Million | -0.124x | +68.48% |
| 2016-12-31 | €49.75 Million | €-19.58 Million | -0.394x | -13.58% |
| 2015-12-31 | €37.11 Million | €-12.86 Million | -0.347x | -1.43% |
| 2014-12-31 | €29.26 Million | €-10.00 Million | -0.342x | +32.56% |
| 2013-12-31 | €21.09 Million | €-10.69 Million | -0.507x | -340.15% |
| 2012-12-31 | €27.61 Million | €5.83 Million | 0.211x | +128.11% |
| 2011-12-31 | €6.58 Million | €-4.94 Million | -0.750x | +52.17% |
| 2010-12-31 | €12.19 Million | €-19.13 Million | -1.569x | -99.27% |
| 2009-12-31 | €29.28 Million | €-23.06 Million | -0.787x | -80.96% |
| 2008-12-31 | €45.81 Million | €-19.93 Million | -0.435x | -80.11% |
| 2007-12-31 | €57.40 Million | €-13.87 Million | -0.242x | -70.22% |
| 2006-12-31 | €67.86 Million | €-9.63 Million | -0.142x | +83.14% |
| 2005-12-31 | €17.02 Million | €-14.33 Million | -0.842x | -- |